ReviewFrontiers in cardiovascular medicine2023
Different heart failure phenotypes of valvular heart disease: the role of mitochondrial dysfunction.
Review in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Immunology of heart failure with preserved ejection fraction.Expert review of clinical immunology · 2025Pooled it
- Association of Valvular Disease Progression Using Echocardiographic Findings in a Large U.S. Cohort.Echocardiography (Mount Kisco, N.Y.) · 2026Article
- Prognostic value of myocardial work indices measured on echocardiography in patients with aortic stenosis undergoing transcatheter aortic valve replacement: A systematic review and meta-analysis.Pakistan journal of medical sciences · 2026Article
- Influence of Phenotypes on Short-Term Outcomes in Hospitalized Heart Failure with Preserved Ejection Fraction-Insights from a North-Eastern Romanian Cohort.Medical sciences (Basel, Switzerland) · 2026Article
- Sex-related disparities in elderly patients with heart failure with mildly reduced or preserved ejection fraction.ESC heart failure · 2026Observational
- Astragaloside IV inhibits MAPK pathway and promotes mitochondrial autophagy in rats with heart failure.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026Article
- A zebrafish model of chronic heart failure caused by protein aggregation in heart valves.Communications biology · 2025Article
- Valvular Heart Disease in Non-Valvular Heart Failure Continuum: The Role of Cardiopulmonary Exercise Testing.Biomedicines · 2025Article
- Multicenter study of heart failure phenotypes and physician-adjudicated causes in people with HIV.AIDS (London, England) · 2025Article
- Clinical Profile of Heart Failure Patients and Evaluation of the Prescribing Practice of Guideline Directed Medical Therapy (GDMT) at Rwanda Military Referral and Teaching Hospital: A Retrospective Study.International journal of general medicine · 2025Article
- Burden and Temporal Trends of Valvular Heart Disease-Related Heart Failure From 1990 to 2019 and Projection Up to 2030 in Group of 20 Countries: An Analysis for the Global Burden of Disease Study 2019.Journal of the American Heart Association · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Valvular heart disease (VHD)-related heart failure (HF) is a special subtype of HF with an increasingly concerned heterogeneity in pathophysiology, clinical phenotypes, and outcomes. The mechanism of VHD-related HF involves not only mechanical damage to the valve itself but also valve lesions caused by myocardial ischemia. The interactions between them will lead to the occurrence and development of VHD-related HF subtypes. Due to the spatial (combination of different valvular lesions) and temporal effects (sequence of valvular lesions) of valvular damages, it can make the patient's condition more complicated and also make the physicians deal with a dilemma when deciding on a treatment plan. This indicates that there is still lack of deep understanding on the pathogenic mechanism of VHD-related HF subtypes. On the other hand, mitochondrial dysfunction (MitD) is not only associated with the development of numerous cardiac diseases such as atherosclerosis, hypertension, diabetes, and HF but also occurs in VHD. However, the role of MitD in VHD-related HF is still not fully recognized. In this comprehensive review, we aim to discuss the current findings and challenges of different valvular damages derived from HF subtypes as well as the role of MitD in VHD-related HF subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.